Filing Details

Accession Number:
0001415889-24-009152
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-26 18:47:24
Reporting Period:
2024-03-22
Accepted Time:
2024-03-26 18:47:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1671858 Ars Pharmaceuticals Inc. SPRY Pharmaceutical Preparations (2834) 811489190
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1951291 Sarina Tanimoto C/O Ars Pharmaceuticals, Inc.
11682 El Camino Real, Suite 120
San Diego CA 92130
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-03-22 1,017 $9.03 1,745,082 No 4 S Indirect By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020
Common Stock Disposition 2024-03-22 1,326 $9.01 1,996,131 No 4 S Indirect By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006
Common Stock Disposition 2024-03-25 47,635 $9.12 1,697,447 No 4 S Indirect By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020
Common Stock Disposition 2024-03-25 47,632 $9.12 1,948,499 No 4 S Indirect By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020
No 4 S Indirect By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006
No 4 S Indirect By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020
No 4 S Indirect By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,276,854 Direct
Common Stock 1,696,494 Indirect By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020
Common Stock 4,126,822 Indirect By Spouse
Footnotes
  1. The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.
  2. The weighted average sales price for the transaction report was $9.0298,and the range of prices were between $9.00 and $9.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.
  3. The Reporting Person is trustee of the trust.
  4. The weighted average sales price for the transaction report was $9.0132,and the range of prices were between $9.00 and $9.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.
  5. The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.
  6. The weighted average sales price for the transaction report was $9.1238,and the range of prices were between $9.03 and $9.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.
  7. The weighted average sales price for the transaction report was $9.1236,and the range of prices were between $9.03 and $9.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.
  8. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.